Elizabeth L.  Hougen net worth and biography

Elizabeth Hougen Biography and Net Worth

Ms. Hougen is our executive vice president of Finance and chief financial officer. As a member of our executive leadership team, Ms. Hougen contributes to the execution of our strategy, including ensuring we are well positioned to be a global, multi-product sustainably profitable company. Ionis’ finance, accounting, tax, treasury, information technology, procurement and investor relations functions report to her. Ms. Hougen joined Ionis in May 2000 as vice president, finance, and became chief accounting officer in January 2007 and chief financial officer in January 2013.

Ms. Hougen has an extensive finance and business background having held positions of increasing responsibility in numerous public companies, primarily in the life sciences industry, over her more than 25-year career. Prior to joining Ionis, Ms. Hougen was chief financial officer for Molecular Biosystems, Inc., a public biotechnology company.

In recognition of her important contributions to the financial success of Ionis, in 2018 Ms. Hougen was named a CFO of the Year by the San Diego Business Journal. Ms. Hougen received her M.B.A. from the University of San Diego and her B.A. from Franklin and Marshall College.

What is Elizabeth L. Hougen's net worth?

The estimated net worth of Elizabeth L. Hougen is at least $3.44 million as of January 31st, 2025. Ms. Hougen owns 110,500 shares of Ionis Pharmaceuticals stock worth more than $3,442,075 as of March 29th. This net worth approximation does not reflect any other assets that Ms. Hougen may own. Additionally, Ms. Hougen receives an annual salary of $1,140,000.00 as CFO at Ionis Pharmaceuticals. Learn More about Elizabeth L. Hougen's net worth.

How old is Elizabeth L. Hougen?

Ms. Hougen is currently 62 years old. There are 6 older executives and no younger executives at Ionis Pharmaceuticals. The oldest executive at Ionis Pharmaceuticals is Ms. B. Lynne Parshall Esq., J.D., Director, who is 70 years old. Learn More on Elizabeth L. Hougen's age.

What is Elizabeth L. Hougen's salary?

As the CFO of Ionis Pharmaceuticals, Inc., Ms. Hougen earns $1,140,000.00 per year. The highest earning executive at Ionis Pharmaceuticals is Dr. Brett P. Monia Ph.D., Founder, CEO & Director, who commands a salary of $2,380,000.00 per year. Learn More on Elizabeth L. Hougen's salary.

How do I contact Elizabeth L. Hougen?

The corporate mailing address for Ms. Hougen and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at wwalke@ionisph.com. Learn More on Elizabeth L. Hougen's contact information.

Has Elizabeth L. Hougen been buying or selling shares of Ionis Pharmaceuticals?

Over the course of the past ninety days, Elizabeth L. Hougen has sold $340,430.82 of Ionis Pharmaceuticals stock. Most recently, Elizabeth L. Hougen sold 1,523 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $32.44, for a transaction totalling $49,406.12. Following the completion of the sale, the chief financial officer now directly owns 110,500 shares of the company's stock, valued at $3,584,620. Learn More on Elizabeth L. Hougen's trading history.

Who are Ionis Pharmaceuticals' active insiders?

Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ionis Pharmaceuticals?

During the last year, Ionis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $181,100.00. During the last year, insiders at the sold shares 18 times. They sold a total of 144,589 shares worth more than $5,063,297.91. The most recent insider tranaction occured on March, 11th when CEO Brett P Monia sold 140 shares worth more than $4,524.80. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.

Information on this page was last updated on 3/11/2025.

Elizabeth L. Hougen Insider Trading History at Ionis Pharmaceuticals

Elizabeth L. Hougen Buying and Selling Activity at Ionis Pharmaceuticals

This chart shows Elizabeth L Hougen's buying and selling at Ionis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$340ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals logo
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Read More

Today's Range

Now: $31.15
Low: $30.80
High: $31.58

50 Day Range

MA: $32.53
Low: $30.35
High: $34.75

2 Week Range

Now: $31.15
Low: $30.23
High: $52.34

Volume

799,700 shs

Average Volume

1,448,598 shs

Market Capitalization

$4.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28